Jayansree Pharma Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 8.00 Cr
as on 17-11-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 38.96 Cr
as on 17-11-2024
- Revenue 98.62%
(FY 2023)
- Profit 115.78%
(FY 2023)
- Ebitda 451.80%
(FY 2023)
- Net Worth 87.14%
(FY 2023)
- Total Assets -10.10%
(FY 2023)
About Jayansree Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 8.00 Cr.
The company currently has active open charges totaling ₹38.96 Cr.
Jagarlamudi Babu, Kiran Nalamothu, Venkata Sura, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100AP2014PTC093395
- Company No.
093395
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 2014
- Date of AGM
19 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jayansree Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Sura  | Director | 22-Mar-2018 | Current |
| Jagarlamudi Babu | Director | 22-Mar-2018 | Current |
| Kiran Nalamothu | Director | 20-Aug-2019 | Current |
| Ranganayukulu Muddana | Director | 22-Mar-2018 | Current |
Financial Performance of Jayansree Pharma.
Jayansree Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 98.62% increase. The company also saw a substantial improvement in profitability, with a 115.78% increase in profit. The company's net worth Soared by an impressive increase of 87.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jayansree Pharma?
In 2023, Jayansree Pharma had a promoter holding of 99.93% and a public holding of 0.06%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cornileus Pharmaceuticals Private LimitedActive 22 years 11 monthsJagarlamudi Babu and Kiran Nalamothu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 07 Feb 2020 | ₹38.96 Cr | Open |
How Many Employees Work at Jayansree Pharma?
Jayansree Pharma has a workforce of 37 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jayansree Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jayansree Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
